ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Forecasted to Post FY2024 Earnings of $3.45 Per Share

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Analysts at Capital One Financial issued their FY2024 earnings estimates for ANI Pharmaceuticals in a report issued on Wednesday, September 11th. Capital One Financial analyst T. Chiang forecasts that the specialty pharmaceutical company will post earnings per share of $3.45 for the year. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.50 per share. Capital One Financial also issued estimates for ANI Pharmaceuticals’ Q4 2024 earnings at $0.92 EPS and FY2025 earnings at $3.88 EPS.

ANIP has been the subject of several other research reports. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. HC Wainwright reiterated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday. Finally, Truist Financial reiterated a “hold” rating and issued a $60.00 target price (down previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $77.75.

ANI Pharmaceuticals Price Performance

ANIP opened at $60.06 on Monday. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of 37.53 and a beta of 0.71. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average price of $61.27 and a 200-day moving average price of $63.85. ANI Pharmaceuticals has a twelve month low of $48.20 and a twelve month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. During the same quarter last year, the company posted $1.06 earnings per share. The firm’s quarterly revenue was up 18.5% compared to the same quarter last year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of ANIP. Allspring Global Investments Holdings LLC lifted its position in ANI Pharmaceuticals by 287.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after purchasing an additional 15,790 shares during the last quarter. Great Lakes Advisors LLC lifted its position in ANI Pharmaceuticals by 67.1% during the fourth quarter. Great Lakes Advisors LLC now owns 48,252 shares of the specialty pharmaceutical company’s stock valued at $2,661,000 after purchasing an additional 19,378 shares during the last quarter. BNP Paribas Financial Markets lifted its position in ANI Pharmaceuticals by 106.9% during the first quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock valued at $1,434,000 after purchasing an additional 10,716 shares during the last quarter. Wakefield Asset Management LLLP bought a new stake in ANI Pharmaceuticals during the first quarter valued at approximately $979,000. Finally, Sequoia Financial Advisors LLC bought a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $600,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Activity at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $58.90, for a total transaction of $1,178,000.00. Following the completion of the transaction, the chief operating officer now owns 682,620 shares of the company’s stock, valued at $40,206,318. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 66,007 shares of company stock valued at $4,089,790. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.